Literature DB >> 28972186

Intramolecular autoinhibition of checkpoint kinase 1 is mediated by conserved basic motifs of the C-terminal kinase-associated 1 domain.

Ryan P Emptage1, Megan J Schoenberger2, Kathryn M Ferguson3, Ronen Marmorstein4,2.   

Abstract

Precise control of the cell cycle allows for timely repair of genetic material prior to replication. One factor intimately involved in this process is checkpoint kinase 1 (Chk1), a DNA damage repair inducing Ser/Thr protein kinase that contains an N-terminal kinase domain and a C-terminal regulatory region consisting of a ∼100-residue linker followed by a putative kinase-associated 1 (KA1) domain. We report the crystal structure of the human Chk1 KA1 domain, demonstrating striking structural homology with other sequentially diverse KA1 domains. Separately purified Chk1 kinase and KA1 domains are intimately associated in solution, which results in inhibition of Chk1 kinase activity. Using truncation mutants and site-directed mutagenesis, we define the inhibitory face of the KA1 domain as a series of basic residues residing on two conserved regions of the primary structure. These findings point to KA1-mediated intramolecular autoinhibition as a key regulatory mechanism of human Chk1, and provide new therapeutic possibilities with which to attack this validated oncology target with small molecules.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  DNA damage response; cell cycle; checkpoint control; crystal structure; enzyme inactivation; enzyme mechanism; protein domain; serine/threonine protein kinase; structural biology

Mesh:

Substances:

Year:  2017        PMID: 28972186      PMCID: PMC5704483          DOI: 10.1074/jbc.M117.811265

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Solution structure of the kinase-associated domain 1 of mouse microtubule-associated protein/microtubule affinity-regulating kinase 3.

Authors:  Naoya Tochio; Seizo Koshiba; Naohiro Kobayashi; Makoto Inoue; Takashi Yabuki; Masaaki Aoki; Eiko Seki; Takayoshi Matsuda; Yasuko Tomo; Yoko Motoda; Atsuo Kobayashi; Akiko Tanaka; Yoshihide Hayashizaki; Takaho Terada; Mikako Shirouzu; Takanori Kigawa; Shigeyuki Yokoyama
Journal:  Protein Sci       Date:  2006-11       Impact factor: 6.725

2.  Regulatory motifs in Chk1.

Authors:  Michael L Caparelli; Matthew J O'Connell
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

3.  Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase.

Authors:  Ryan P Emptage; Mark A Lemmon; Kathryn M Ferguson
Journal:  Biochem J       Date:  2016-11-22       Impact factor: 3.857

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

5.  Conformational Change of Human Checkpoint Kinase 1 (Chk1) Induced by DNA Damage.

Authors:  Xiangzi Han; Jinshan Tang; Jingna Wang; Feng Ren; Jinhua Zheng; Megan Gragg; Philip Kiser; Paul S H Park; Krzysztof Palczewski; Xinsheng Yao; Youwei Zhang
Journal:  J Biol Chem       Date:  2016-04-18       Impact factor: 5.157

6.  KA1-targeted regulatory domain mutations activate Chk1 in the absence of DNA damage.

Authors:  Eun-Yeung Gong; Veronique A J Smits; Felipe Fumagallo; Desiree Piscitello; Nick Morrice; Raimundo Freire; David A Gillespie
Journal:  Sci Rep       Date:  2015-06-03       Impact factor: 4.379

7.  Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.

Authors:  Yao Zhang; Jinzhi Lai; Zhanwen Du; Jinnan Gao; Shuming Yang; Shashank Gorityala; Xiahui Xiong; Ou Deng; Zhefu Ma; Chunhong Yan; Gonzalo Susana; Yan Xu; Junran Zhang
Journal:  Oncotarget       Date:  2016-06-07

Review 8.  Targeting the ATR-CHK1 Axis in Cancer Therapy.

Authors:  Stuart Rundle; Alice Bradbury; Yvette Drew; Nicola J Curtin
Journal:  Cancers (Basel)       Date:  2017-04-27       Impact factor: 6.639

9.  Regulation of chk1.

Authors:  Claudia Tapia-Alveal; Teresa M Calonge; Matthew J O'Connell
Journal:  Cell Div       Date:  2009-04-29       Impact factor: 5.130

10.  Importance of a C-terminal conserved region of Chk1 for checkpoint function.

Authors:  Carmela Palermo; Justin C Hope; Greg A Freyer; Hui Rao; Nancy C Walworth
Journal:  PLoS One       Date:  2008-01-09       Impact factor: 3.240

View more
  6 in total

1.  Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain.

Authors:  Ryan P Emptage; Mark A Lemmon; Kathryn M Ferguson; Ronen Marmorstein
Journal:  Structure       Date:  2018-06-28       Impact factor: 5.006

2.  Direct regulation of Chk1 protein stability by E3 ubiquitin ligase HUWE1.

Authors:  Katelyn B Cassidy; Scott Bang; Manabu Kurokawa; Scott A Gerber
Journal:  FEBS J       Date:  2019-11-29       Impact factor: 5.542

3.  Structural basis for recruitment of the CHK1 DNA damage kinase by the CLASPIN scaffold protein.

Authors:  Matthew Day; Sarah Parry-Morris; Jack Houghton-Gisby; Antony W Oliver; Laurence H Pearl
Journal:  Structure       Date:  2021-03-30       Impact factor: 5.006

4.  Chk1 KA1 domain auto-phosphorylation stimulates biological activity and is linked to rapid proteasomal degradation.

Authors:  Eun-Yeung Gong; Beatriz Hernández; Jessica Hernández Nielsen; Veronique A J Smits; Raimundo Freire; David A Gillespie
Journal:  Sci Rep       Date:  2018-12-03       Impact factor: 4.379

5.  Dominant mutations in CHK1 cause pronuclear fusion failure and zygote arrest that can be rescued by CHK1 inhibitor.

Authors:  Honghui Zhang; Tailai Chen; Keliang Wu; Zhenzhen Hou; Shigang Zhao; Chuanxin Zhang; Yuan Gao; Ming Gao; Zi-Jiang Chen; Han Zhao
Journal:  Cell Res       Date:  2021-05-06       Impact factor: 25.617

6.  Maternal heterozygous mutation in CHEK1 leads to mitotic arrest in human zygotes.

Authors:  Beili Chen; Jianying Guo; Ting Wang; Qianhui Lee; Jia Ming; Fangfang Ding; Haitao Li; Zhiguo Zhang; Lin Li; Yunxia Cao; Jie Na
Journal:  Protein Cell       Date:  2021-05-04       Impact factor: 14.870

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.